Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Prognostic Value of Baseline Serum Neurofilament Light Chain Levels in People with Relapsing Multiple Sclerosis by Prior Treatment Status and DMT Type

              Author:Bittner, Stefan   H. Cross, Anne   Pardo, Gabriel   S. Zamvil, Scott   Bhatt, Alit   Wei, Wenjia   Boer, Ibolya   Thouvenot, Eric   Ziemssen, Tjalf   

              Session Name:P5: Multiple Sclerosis: Biomarkers and Immunology 1  

              Topic:Multiple Sclerosis  

              Program Number:P5.009  

              Author Institution:Department of Neurology, University Medical Center of Johannes Gutenberg University Mainz, Mainz, Germany, Mainz, Germany  Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Oklahoma City, OK  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Department of Neurology, Centre Hospitalier Universitaire (CHU) Nîmes, University of Montpellier, Nîmes, France, Nimes Cedex 9, France  

              Continuous Ofatumumab Treatment Up to 7 Years Shows a Consistent Safety Profile and Delays Disability Progression in People with Relapsing Multiple Sclerosis

              Author:Pardo, Gabriel   Bar-Or, Amit   Montalban, Xavier   Nakahara, Jin   Morrow, Sarah A.   Bhatt, Alit   Wu, Min   Pearce, Gregory Lewis   Sullivan, Roseanne   Abeyewickreme, Anil   de Seze, Jérôme   Wiendl, Heinz   Hauser, Stephen L.   

              Session Name:P7: Multiple Sclerosis: Disease-modifying Therapies: Real-world Evidence and Adverse Events 1  

              Topic:Multiple Sclerosis  

              Program Number:P7.016  

              Author Institution:Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Oklahoma City, OK  Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  Department of Neurology/Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcolena, Spain  Department of Neurology, Keio University School of Medicine, Tokyo, Japan, Tokyo, Japan  Novartis Healthcare Pvt Ltd, Hyderabad, India, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Novartis Pharmaceuticals UK Ltd, London, UK, London, United Kingdom  University Hospital of Strasbourg, Strasbourg, France, Strasbourg, France  Klinik für Neurologie und Neurophysiologie, Universitätsklinikum Freiburg, Freiburg, Germany, Freiburg, Germany  

              Long-term Ofatumumab Treatment Over 6 Years Did Not Increase the Risk of Serious Infections

              Author:Wiendl, Heinz   Meuth, Sven   Pardo, Gabriel   Zamvil, Scott   Boer, lbolya   Bhatt, Alit   Wu, Min   Hu, Xixi   Jehl, Valentine   Sullivan, Roseanne   Montalban, Xavier   Cohen, Jeffrey   

              Session Name:P8: Multiple Sclerosis: Disease-modifying Therapies: Real-world Evidence and Adverse Events 2  

              Topic:Multiple Sclerosis  

              Program Number:P8.017  

              Author Institution:Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany, Muenster, Germany  Department of Neurology, Medical Faculty, Heinrich-Heine-University, Dusseldorf, Germany, Duesseldorf, Germany  Oklahoma Medical Research Foundation, OK, USA, Oklahoma City, OK  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Morristown, NJ  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ